Clinicians
A Key Clinical Reality
Many infants with 16p11.2 genetic variance look typical at birth. There are no single physical features that reliably flag the diagnosis early. This seeming normalcy, combined with the later emergence of multiple medical and developmental needs, was identified by families as one of the largest sources of stress. In our Foundation survey of approximately 200 individuals and families, caregivers repeatedly described how difficult it was that their child appeared typical while experiencing numerous medical challenges often undertreated by clinicians.
That is why developmental surveillance and early action matter.
Recent work in autism highlights that children can follow different developmental paths. Some children meet early milestones and then diverge later. Others show early developmental delays that can widen over time if not addressed. Differences in the timing of affected genes align with differences in milestones and later outcomes.
This is the practical takeaway for your clinic.
- If a child is not meeting milestones in the window expected for age, do not wait.
- The gap can grow as the child gets older because new skills build on earlier skills.
- Early intervention is not optional. It is protective.
A clinical review written to support primary care clinicians caring for 16p11.2 deletion emphasizes that prompt attention to issues helps optimize lifelong outcomes.
What Families Are Telling Us
In our Foundation survey of about 200 individuals and caregivers, nearly all reported that at the time of diagnosis their doctor knew little or nothing about 16p11.2 genetic variances.
For a family, this can be frightening. The worst feeling is not only that a doctor does not know, but that the doctor is not interested in learning.
We are asking clinicians to take the lead in closing this gap.
Communication that Helps and Communication that Harms
Families need clarity and action.
Helpful:
- “I may not know this condition well yet, but I will learn, and we will build a plan together.”
- “Your concerns are valid. Let’s evaluate and refer early.”
Harmful:
- “They will catch up.”
- “Let’s wait and see.”
False reassurance can delay therapy and widen developmental gaps.
Think Whole Child
Many clinicians work within narrow lanes. 16p11.2 genetic variance does not.
Because gene dosage differences can affect multiple body systems, children may have needs across many areas. A published health supervision review for 16p11.2 deletion describes a broad range of neurodevelopmental and medical concerns that can require monitoring and specialty care.
Areas that often need attention can include:
- Neurodevelopmental and learning
- Speech and language
- Neurology and seizures
- Sleep
- Behavioral and psychiatric health
- Growth, nutrition, and metabolism
- Endocrinology
- Vision and ophthalmology
- Hearing and auditory processing
- Musculoskeletal and orthopedic concerns
- Head and neck, dental, and orthodontic care
- Gastrointestinal concerns
- Skin
- Immune and infection patterns
- Hematology when clinically indicated
Some children will have mild needs in one area. Others will have complex needs across many areas. Do not judge need by appearance in a brief visit.
If You are Not Comfortable, Help Families Find the Right Care
These children may be among the most complex patients you manage. If you are not comfortable with a concern, refer early.
Also, please partner with families on access.
- Document medical necessity clearly.
- Support referrals and therapies.
- Advocate with insurance when appropriate.
Delays in evaluation or access will cause harm.
Judicious Use of Medications, Including Off-Label Care
At this time, there are no medications specifically approved or indicated for 16p11.2 genetic variances. Families and clinicians are therefore navigating care in a space where evidence is emerging, but condition‑specific pharmacologic options remain limited.
Children with 16p11.2 genetic variances often present with symptoms for which there is not yet an FDA‑approved, condition‑specific medication. In these situations, thoughtful off‑label medication use may be appropriate when there is a strong pathophysiologic rationale and when care is guided by relevant specialty expertise.
Key principles we encourage clinicians to follow include:
- Anchor decisions in underlying pathophysiology and mechanism, not just surface behaviors
- Involve appropriate specialists such as neurology, psychiatry, endocrinology, or metabolic specialists when considering off‑label therapy
- Engage families in transparent, shared decision‑making, including clear discussion of known benefits, uncertainties, and potential risks
- Start low, go slow, and monitor closely with predefined goals and stop criteria
- Reassess frequently and adjust based on objective response and family‑reported outcomes
When families understand the rationale and risks, they are informed partners rather than passive recipients of care. Avoiding treatment simply because a use is off‑label can also cause harm when symptoms are impairing development, learning, or health.
Structural Barriers that Compound Harm
At present, there is also no ICD code specific to 16p11.2 genetic variances. This absence creates real and ongoing barriers for families, including difficulties with care coordination, insurance coverage, referrals, and data tracking.
For clinicians and families alike, this gap is more than administrative. It affects access, documentation, and ultimately outcomes. We view this as a serious and addressable problem.
Our Foundation is actively advocating for development and adoption of appropriate ICD coding to better reflect the medical complexity and lifelong nature of 16p11.2‑related conditions. This effort requires collaboration across disciplines.
We invite clinicians from all specialties who are interested in contributing to this advocacy work, sharing clinical ifnsight, or participating in guideline and policy development to contact us. Your expertise and partnership are essential as we work toward systems that better support patients and families.
Our pathophysiology materials, resource library, and ongoing clinical guideline efforts are designed to support clinicians in making these decisions carefully, collaboratively, and responsibly.
Our Resource Library
We maintain a growing Resource Library designed to support clinicians at the point of care. This library brings together peer‑reviewed literature, clinical reviews, consensus guidance, and practical tools relevant to 16p11.2 genetic variances.
Resources you will find include:
- Summaries of key research findings translated into clinical takeaways
- Primary care and specialty considerations across the lifespan
- Links to foundational references such as GeneReviews and major cohort studies
- Educational materials to support conversations with families
This library reflects our Phase 1 work and will continue to expand as new evidence emerges and clinical guidance evolves. We aim to make it easier for clinicians to access reliable, up‑to‑date information without having to search across multiple platforms.
Start Here on Our Site
Our founder is a physician and a parent, and we are building resources to make this easier for clinicians.
Suggested starting points:
- Understanding Pathophysiology
- Clinical Guidelines for Primary Care
“Health supervision for children and adolescents with 16p11.2 deletion syndrome” (Molecular Case Studies, 2023). - GeneReviews and core references
GeneReviews summary pages are a helpful starting point for diagnosis, management, and surveillance. - Child friendly education tools
We created children’s books to help families and clinics explain genes, DNA, and 16p11.2 in a calm, age‑appropriate way. - Conferences and shared learning
We invite clinicians to attend our conferences to learn from experts and families. - Specialty care guidelines in development
We are actively working toward specialty care guidance across key domains. More information coming soon.